Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function
Status:
Completed
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
This si a single-center, non-randomized, open, parallel, single-dose trial was designed to
evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with
impaired liver function.